Clinical Trial

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.
Trial Details
NCT Number NCT07195032
Lead Sponsor Children's Mercy Hospital Kansas City
Conditions Heart Transplant Infection Prevention
Enrollment 60 participants
Start Date 2025-09-11
Primary Completion 2027-09-11 (estimated)
Study Completion 2027-09-11 (estimated)
Updated on ClinicalTrials.gov 2025-09-26